Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025

Core Insights - Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for hypertension and related comorbidities [3] - The company will report its financial results for the second quarter ended June 30, 2025, on August 12, 2025, after market close [1][2] Company Overview - Mineralys Therapeutics specializes in medicines targeting hypertension, hypertensive nephropathy, obstructive sleep apnea, and diseases driven by dysregulated aldosterone [3] - The company's lead product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor [3] - Mineralys is headquartered in Radnor, Pennsylvania, and was founded by Catalys Pacific [3]